New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lobe Sciences Ltd. (OTCQB:LOBEF), the Vancouver-based life sciences company focused on developing transformational psychedelic medicines through drug R&A, recently announced the implementation of a consolidation of their common shares on the basis of one post-consolidation share for every six pre-consolidation shares. The measure will become effective on June 9.
波叶科学有限公司(OTCQB：LOBEF)，这家总部位于温哥华的生命科学公司专注于通过药物研发开发变革性迷幻药物，最近宣布实施合并后普通股合并，即每六股合并前股票对应一股合并后普通股。该措施将于6月9日生效。
The company's R&A approach involves predominantly studies of psychedelics psilocybin and MDMA combined with NAC in microdoses for the treatment of mTBI and PTSD, as well as patenting pending medical devices and a virtual reality integration to improve efficiency and raise response to treatment.
该公司的研发方法主要涉及迷幻剂裸盖菇素和MDMA与小剂量NAC联合治疗mTBI和创伤后应激障碍的研究，以及正在申请专利的医疗设备和虚拟现实集成，以提高效率和提高治疗反应。
Philip J. Young, CEO & director of Lobe Sciences, presented at the 2021 Benzinga Healthcare Small Cap Conference on psychedelics and transformative medicine.
波瓣科学首席执行官兼董事首席执行官菲利普·J·杨，在2021年Benzinga Healthcare Small Cap大会迷幻药和变革性医学。
Besides their presence at the venture market (OTCQB), the company began trading at the Canadian Securities Exchange (CSE) back in November 2020 under the trading symbol "LOBE". The new consolidation will not change the Company's name nor its trading symbols to date.
除了他们在风险投资市场(OTCQB)的存在外，该公司还开始在加拿大证券交易所(CSE)早在2020年11月，交易代码就是“波瓣到目前为止，新的合并不会改变公司的名称或其交易代码。
According to a recent press release, the company currently has 229,383,983 shares issued and outstanding. Following the consolidation, there will be approximately 38,230,000 Shares issued and outstanding. No fractional shares will be issued, and any fraction of a share will be rounded up to the nearest whole number of shares.
根据最近的新闻稿，该公司目前已发行和已发行的股票为229,383,983股。合并后，将有大约38,230,000股已发行和流通股。不会发行零碎股份，任何零碎股份都将四舍五入为最接近的整数股。
The shares will trade on a post-consolidation basis under the new CUSIP #53946V206 and ISIN #CA53946V2066. They are expected to begin trading on the post-consolidation basis on the CSE when markets open on June 9.
这些股票将在合并后的基础上根据新的CUSIP#53946V206和ISIN#CA53946V2066进行交易。预计它们将在6月9日开盘时开始在CSE进行整合后的交易。
Regarding the exercise or conversion price and the number of shares issuable under any of the company's outstanding convertible securities, they will be proportionately adjusted upon the effectiveness of the consolidation.
关于行使或转换价格以及根据公司任何已发行可转换证券可发行的股份数量，将根据合并的有效性按比例进行调整。